Group 1 - The core point of the article is that Ruizhi Pharmaceutical (300149) announced that shareholders Liang Yufeng and Yu Xianwen plan to collectively reduce their holdings by up to 6% of the company's shares [1] Group 2 - Shareholder Liang Yufeng, who holds 26.1857 million shares (5.26% of total shares), intends to reduce his holdings by up to 14.9389 million shares (3% of total shares) within three months after a 15 trading day period from the announcement date [1] - Shareholder Yu Xianwen, who holds 25 million shares (5.02% of total shares), also plans to reduce his holdings by up to 14.9389 million shares (3% of total shares) within the same timeframe [1]

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings by a total of 14.9389 million shares, representing 3% of the company's total share capital, within three months after a 15-trading-day notice period [1] Group 1: Shareholder Actions - Shareholder Liang Yufeng intends to reduce her stake by up to 14.9389 million shares, which is 3% of the total share capital, through centralized bidding or block trading within three months after the notice period [1] - Shareholder Yu Xianwen also plans to reduce his holdings by the same amount of 14.9389 million shares, accounting for 3% of the total share capital, using similar methods within the specified timeframe [1]

Core Viewpoint - The major shareholders of Ruizhi Pharmaceutical (300149.SZ) plan to reduce their holdings by a total of 14.9389 million shares, representing 3% of the company's total share capital, within three months after a 15-trading-day period from the announcement date [1] Shareholder Reduction Plans - Shareholder Liang Yufeng intends to reduce her stake by up to 14.9389 million shares, which is 3% of the total share capital, through centralized bidding or block trading within three months after the specified period [1] - Shareholder Yu Xianwen also plans to reduce his holdings by the same amount of 14.9389 million shares, accounting for 3% of the total share capital, using similar methods within the same timeframe [1]

21智讯1月15日电，睿智医药公告，持股5%以上股东梁玉凤、于显文计划在本公告披露之日起十五个交 易日后的三个月内，以集中竞价或大宗交易方式减持公司股份。梁玉凤持有公司26,185,660股（占总股 本5.26%），拟减持不超过14,938,919股（占总股本3%）；于显文持有公司25,000,000股（占总股本 5.02%），拟减持不超过14,938,919股（占总股本3%）。减持原因为自身资金需求，股份来源为协议转 让取得。减持期间为2026年2月6日至2026年5月5日，减持方式为集中竞价或大宗交易，价格区间视市场 情况确定。两位股东均非公司控股股东、实际控制人及其一致行动人，本次减持不会导致公司控制权变 更，也不会对公司治理结构及持续经营产生影响。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2026-01 睿智医药科技股份有限公司 关于持股 5%以上股东减持股份的预披露公告 持股5%以上股东梁玉凤、于显文保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有睿智医药科技股份有限公司（以下简称"公司"）股份 26,185,660 股（占公司总股本比例 5.26%）的持股 5%以上股东梁玉凤女士计划在本公告披露 之日起十五个交易日后的三个月内以集中竞价或大宗交易方式减持公司股份不超 过 14,938,919 股（占公司总股本比例 3%）。 2、持有公司股份 25,000,000 股（占公司总股本比例 5.02%）的持股 5%以上 股东于显文先生计划在本公告披露之日起十五个交易日后的三个月内以集中竞价 或大宗交易方式减持公司股份不超过 14,938,919 股（占公司总股本比例 3%）。 公司于近日收到持股 5%以上股东梁玉凤女士、于显文先生分别出具的《关 于股份减持计划告知函》，现将相关情况公告如下： | 股东名称 | 持股数量（ ...

Group 1 - The core viewpoint of the articles highlights Ruizhi Pharmaceutical's active advancements in the field of small nucleic acid drug research and production, driven by technological innovation and strategic partnerships to enhance its full-chain service capabilities from laboratory to industrialization [1][2] Group 2 - Ruizhi Pharmaceutical, in collaboration with East China Normal University, launched a drug manufacturing system suitable for ADC and nucleotide monomer synthesis, significantly reducing ADC drug process development time by 70% and lowering nucleotide monomer synthesis costs by over 40% [1] - The company has developed hundreds of modified nucleotides, phosphoramidite monomers, and new linkers, leveraging its capabilities in chemical synthesis and early-stage process development [1] - The company is focusing on delivery system efficiency, which is crucial for the successful commercialization of small nucleic acid drugs, by adopting a phased strategy in collaboration with partners like Haiyou Biotechnology [1] - Ruizhi Pharmaceutical is innovatively integrating Corporate Venture Capital (CVC) and AI-driven scientific research (AI4S) into its strategic layout to enhance project selection and build a technological ecosystem [2] - The chairman of Ruizhi Pharmaceutical emphasized that the computational medicine platform of Zheyuan Technology complements CRO services, aiming to unlock the full potential of the industry by identifying effective research directions [2] - The company aims to build differentiated competitive advantages in small nucleic acid drug research through cost reduction and efficiency improvements, breakthroughs in delivery technology, and expanded applications via full-cycle collaborations [2]

Core Insights - Ruizhi Pharmaceutical Technology Co., Ltd. has developed two automated integrated micro-flow synthesis systems based on its "Super Limit Intelligent Manufacturing" platform, which are currently applied internally to enhance R&D in ADC and small nucleic acid drug fields [1][2] Group 1: Technology and Innovation - The internal application of the Super Limit Intelligent Manufacturing platform focuses on two main areas: enhancing the coupling process for antibody-drug conjugates (ADCs) and synthesizing nucleoside monomers for oligonucleotide drugs, significantly improving development efficiency and overall yield [1] - The ADC drug process development time can be reduced by 70%, while the cost of synthesizing nucleoside monomers can be lowered by over 40% [2] Group 2: Strategic Partnerships and Market Positioning - The drug manufacturing system was jointly released by Ruizhi Pharmaceutical and East China Normal University, emphasizing the establishment of a joint laboratory to improve the transition from laboratory R&D to industrial production [2] - The company is positioning its business around "new modalities (including small nucleic acids)" and "ecological investment," aiming to create more opportunities in the small nucleic acid sector through strategic partnerships with multiple companies [2]

Market Overview - The A-share market experienced a narrow fluctuation with the Shanghai Composite Index down 0.03% at 4163.84 points, the Shenzhen Component down 0.31% at 14321.8 points, and the ChiNext Index down 0.83% at 3360.23 points, as well as the STAR Market Index down 1.77% at 1485.01 points, with a total trading volume of 2.44 trillion yuan and over 2800 stocks declining [1] Hot Sectors - The AI application sector led the market, with stocks like Easy Point World, Liou Shares, and Gravity Media hitting the daily limit, while AI medical concepts remained active with companies like Meian Health and Dean Diagnostics achieving three consecutive limit-ups [2][1] - The innovative drug sector saw significant gains, with Hongbo Pharmaceutical hitting the daily limit and other companies like Chengdu Xian Dao and Rui Zhi Pharmaceutical rising over 10% [3] - The insurance sector remained active, with China Life rising over 4% and other major insurers following suit, driven by policy support and macroeconomic changes [4] Securities Sector - The securities sector showed a rising trend, with Huayin Securities hitting the limit and other firms like Founder Securities and GF Securities also experiencing gains [5] Trading Volume - The trading volume in the Shanghai and Shenzhen markets reached a record high of 3.6 trillion yuan, indicating strong market activity [6] Institutional Insights - Zhongtai Securities noted that the market may maintain active trading under policy support, with long-term funds providing a necessary liquidity condition [7] - Dongfang Securities commented on the current healthy market trend, despite concerns about potential adjustments due to increased trading volume [8][9] - CITIC Securities highlighted the potential impact of the cancellation of export tax rebates for the photovoltaic industry, suggesting short-term challenges but long-term opportunities for high-quality development [10]

目前，市场最担心的仍是成交量持续放大之后的调整风险。对此，中泰证券表示，长线资金托底，政策 推动下市场或维持交投活跃。东方证券认为，从历史经验来看，成交量持续放大之后，的确会引起市场 波动，尤其在沪综指17连阳且逼近4200点之时。 热门板块 1、AI应用领涨市场 以GEO、制药为首等AI应用方向领涨市场，易点天下、利欧股份、浙文互联、引力传媒、博瑞传播3连 板，天龙集团、值得买高开超10%。 1月13日，三大指数高开低走，截至发稿，沪指跌0.57%，深证成指跌0.63%，创业板指跌0.59%。 盘面上，以GEO、制药为首等AI应用方向领涨市场，易点天下、通达海、迪安诊断20CM涨停；创新药 概念股走强，泓博医药20cm涨停；商业航天板块早盘走低，西部材料、雷科防务、航天发展、航天机 电、中国卫通等多股跌停。 | | AI应用(02GN2343) | | + 板块 | | --- | --- | --- | --- | | | 1746.01 +41.26 +2.42% | | | | 股票名称 | 最新价 | 主力净流入 | 涨跌幅 | | 易点天下 图 301171 | 75.88 | -1.4亿 | + ...

Group 1 - The innovative drug concept stocks opened strong, with Hongbo Pharmaceutical hitting the daily limit up of 20% [1] - Chengdu Xian Dao and Ruizhi Pharmaceutical both rose over 10% [1] - Yaoshi Technology, Boji Pharmaceutical, Meidixi, and Haoyuan Pharmaceutical all increased by more than 5% [1]